Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE-EPI: Lamivudine PrEP for Infant HIV Prevention
NCT03870438Phase 3Completed
- Sponsor
- ANRS
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Prevention of HIV-1 transmission from HIV-1-positive mothers to their breastfeeding children at 12 months. Started Dec 2019; status: completed.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03870438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870438.